Trial · NCT04194944
Adverse events318
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 318
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Selpercatinib (TRT A) | 18 | 158 | 35 |
| other | Anaemia | Blood and lymphatic system disorders | Carboplatin or Cisplatin+Pemetrexed+/-Pembrolizumab (TRT B) | 57 | 98 | 209 |
| other | Leukopenia | Blood and lymphatic system disorders | Selpercatinib (TRT A) | 11 | 158 | 22 |
| other | Leukopenia | Blood and lymphatic system disorders | Carboplatin or Cisplatin+Pemetrexed+/-Pembrolizumab (TRT B) | 8 | 98 | 37 |
| other | Neutropenia | Blood and lymphatic system disorders | Selpercatinib (TRT A) | 6 | 158 | 13 |
| other | Neutropenia | Blood and lymphatic system disorders | Carboplatin or Cisplatin+Pemetrexed+/-Pembrolizumab (TRT B) | 18 | 98 | 61 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Selpercatinib (TRT A) | 11 | 158 | 17 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Carboplatin or Cisplatin+Pemetrexed+/-Pembrolizumab (TRT B) | 10 | 98 | 20 |
| other | Hyperthyroidism | Endocrine disorders | Selpercatinib (TRT A) | 4 | 158 | 8 |
| other | Hyperthyroidism | Endocrine disorders | Carboplatin or Cisplatin+Pemetrexed+/-Pembrolizumab (TRT B) | 7 | 98 | 7 |
| other | Hypothyroidism | Endocrine disorders | Selpercatinib (TRT A) | 5 | 158 | 7 |
| other | Hypothyroidism | Endocrine disorders | Carboplatin or Cisplatin+Pemetrexed+/-Pembrolizumab (TRT B) | 6 | 98 | 10 |
| other | Lacrimation increased | Eye disorders | Selpercatinib (TRT A) | 3 | 158 | 5 |
| other | Lacrimation increased | Eye disorders | Carboplatin or Cisplatin+Pemetrexed+/-Pembrolizumab (TRT B) | 13 | 98 | 16 |
| other | Abdominal discomfort | Gastrointestinal disorders | Selpercatinib (TRT A) | 9 | 158 | 9 |
| other | Abdominal discomfort | Gastrointestinal disorders | Carboplatin or Cisplatin+Pemetrexed+/-Pembrolizumab (TRT B) | 3 | 98 | 3 |
| other | Abdominal distension | Gastrointestinal disorders | Selpercatinib (TRT A) | 8 | 158 | 11 |
| other | Abdominal distension | Gastrointestinal disorders | Carboplatin or Cisplatin+Pemetrexed+/-Pembrolizumab (TRT B) | 3 | 98 | 3 |
| other | Abdominal pain | Gastrointestinal disorders | Selpercatinib (TRT A) | 18 | 158 | 34 |
| other | Abdominal pain | Gastrointestinal disorders | Carboplatin or Cisplatin+Pemetrexed+/-Pembrolizumab (TRT B) | 7 | 98 | 11 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04194944/events